ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bisoffi Z et al. 2013. Strongyloides stercoralis: a plea for action. PLoS Negl Trop Dis 7: e2214.
-
2.
Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X, 2014. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis 8: e3018.
-
3.
Mobley CM, Dhala A, Ghobrial RM, 2017. Strongyloides stercoralis in solid organ transplantation: early diagnosis gets the worm. Curr Opin Organ Transpl 22: 336–344.
-
4.
Mejia R, Nutman T, 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25: 458–463.
-
5.
Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z, 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 78–88.
-
6.
US FDA, Stromectal® (Ivermectin). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050742s022lbl.pdf. Accessed May 5, 2018.
-
7.
Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W, 2016. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother 71: 220–225.
-
8.
Looke DFM, McCarthy KL, McWhinney B, Clague A, Pillans P, 2005. Strongyloides hyperinfection syndrome: low serum levels of ivermectin after oral and subcutaneous administration. Intern Med J 35: A73–A88.
-
9.
Albonico M et al. 2016. StrongNet: an international network to improve diagnostics and access to treatment for strongyloidiasis control. PLoS Negl Trop Dis 10: e0004898.
-
10.
Einsiedel L, Fernandes L, 2008. Strongyloides stercoralis: a cause of morbidity and mortality for indigenous people in central Australia. Intern Med J 38: 697–703.
-
11.
Abdolrasouli A, McMillan A, Ackers JP, 2009. Sexual transmission of intestinal parasites in men who have sex with men. Sex Health 6: 185–194.
-
12.
Qu Z, Kundu UR, Abadeer RA, Wanger A, 2009. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 40: 572–577.
-
13.
Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC, 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 1122–1133.
-
14.
Edwards G, 2003. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2 (Suppl 1): S8.
-
15.
González Canga A, Sahagún Prieto AM, Diez-Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ, 2008. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 10: 42–46.
-
16.
Steel JW, 1993. Pharmacokinetics and metabolism of avermectins in livestock. Vet Parasitol 48: 45–57.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 224 | 161 | 19 |
| Full Text Views | 597 | 14 | 0 |
| PDF Downloads | 251 | 14 | 0 |
Case Report: Subcutaneous Ivermectin Pharmacokinetics in Disseminated Strongyloides Infection: Plasma and Postmortem Analysis
Pamela Konecny
Pamela Konecny
St. George Hospital, Sydney, Australia;
University of New South Wales, Sydney, Australia;
Search for other papers by Pamela Konecny in
Current site
Google Scholar
PubMed
University of New South Wales, Sydney, Australia;
Search for other papers by Pamela Konecny in
Current site
Google Scholar
PubMed
Christopher J. Weatherall
Christopher J. Weatherall
St. George Hospital, Sydney, Australia;
University of New South Wales, Sydney, Australia;
Search for other papers by Christopher J. Weatherall in
Current site
Google Scholar
PubMed
University of New South Wales, Sydney, Australia;
Search for other papers by Christopher J. Weatherall in
Current site
Google Scholar
PubMed
Suman Adhikari
Suman Adhikari
St. George Hospital, Sydney, Australia;
University of New South Wales, Sydney, Australia;
Search for other papers by Suman Adhikari in
Current site
Google Scholar
PubMed
University of New South Wales, Sydney, Australia;
Search for other papers by Suman Adhikari in
Current site
Google Scholar
PubMed
Johan Duflou
Johan Duflou
Forensic Medicine Associates P/L, Sydney, Australia;
University of Sydney, Sydney, Australia;
Search for other papers by Johan Duflou in
Current site
Google Scholar
PubMed
University of Sydney, Sydney, Australia;
Search for other papers by Johan Duflou in
Current site
Google Scholar
PubMed
Veli Marjoniemi
Veli Marjoniemi
St. George Hospital, Sydney, Australia;
University of New South Wales, Sydney, Australia;
Search for other papers by Veli Marjoniemi in
Current site
Google Scholar
PubMed
University of New South Wales, Sydney, Australia;
Search for other papers by Veli Marjoniemi in
Current site
Google Scholar
PubMed
Carel J. Pretorius
Carel J. Pretorius
Pathology Queensland, Brisbane, Australia;
School of Biomedical Sciences, University of Queensland, Brisbane, Australia
Search for other papers by Carel J. Pretorius in
Current site
Google Scholar
PubMed
School of Biomedical Sciences, University of Queensland, Brisbane, Australia
Search for other papers by Carel J. Pretorius in
Current site
Google Scholar
PubMed
Brett McWhinney
Brett McWhinney
Pathology Queensland, Brisbane, Australia;
Search for other papers by Brett McWhinney in
Current site
Google Scholar
PubMed
Search for other papers by Brett McWhinney in
Current site
Google Scholar
PubMed
Parenteral ivermectin treatment of disseminated strongyloidiasis and hyperinfection is increasing, although not licensed in humans and with limited pharmacokinetic data available. Plasma and postmortem tissue analysis in an human immunodeficiency virus (HIV)/hepatitis C virus–positive man with disseminated strongyloidiasis suggests loading subcutaneous ivermectin doses are required, from which the central nervous system is protected.
Author Notes
Authors’ addresses: Pamela Konecny and Christopher J. Weatherall, Department of Infectious Diseases, Immunology and Sexual Health, St. George Hospital, Sydney, Australia, E-mails: pam.konecny@health.nsw.gov.au and chris.weatherall@health.nsw.gov.au. Suman Adhikari, Department of Pharmacy, St. George Hospital, Sydney, Australia, E-mail: suman.adhikari@health.nsw.gov.au. Johan Duflou, Forensic Medicine Associates P/L, Sydney, Australia, E-mail: jduflou@forensicmedicine.com.au. Veli Marjoniemi, Department of Anatomical Pathology, St. George Hospital, Sydney, Australia, E-mail: veli.marjoniemi@health.nsw.gov.au. Carel J. Pretorius and Brett McWhinney, Pathology Queensland, Brisbane, Australia, E-mails: carel.pretorius@health.qld.gov.au and brett.mcwhinney@health.qld.gov.au.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Bisoffi Z et al. 2013. Strongyloides stercoralis: a plea for action. PLoS Negl Trop Dis 7: e2214.
-
2.
Puthiyakunnon S, Boddu S, Li Y, Zhou X, Wang C, Li J, Chen X, 2014. Strongyloidiasis—an insight into its global prevalence and management. PLoS Negl Trop Dis 8: e3018.
-
3.
Mobley CM, Dhala A, Ghobrial RM, 2017. Strongyloides stercoralis in solid organ transplantation: early diagnosis gets the worm. Curr Opin Organ Transpl 22: 336–344.
-
4.
Mejia R, Nutman T, 2012. Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis. Curr Opin Infect Dis 25: 458–463.
-
5.
Buonfrate D, Requena-Mendez A, Angheben A, Muñoz J, Gobbi F, Van Den Ende J, Bisoffi Z, 2013. Severe strongyloidiasis: a systematic review of case reports. BMC Infect Dis 13: 78–88.
-
6.
US FDA, Stromectal® (Ivermectin). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050742s022lbl.pdf. Accessed May 5, 2018.
-
7.
Barrett J, Broderick C, Soulsby H, Wade P, Newsholme W, 2016. Subcutaneous ivermectin use in the treatment of severe Strongyloides stercoralis infection: two case reports and a discussion of the literature. J Antimicrob Chemother 71: 220–225.
-
8.
Looke DFM, McCarthy KL, McWhinney B, Clague A, Pillans P, 2005. Strongyloides hyperinfection syndrome: low serum levels of ivermectin after oral and subcutaneous administration. Intern Med J 35: A73–A88.
-
9.
Albonico M et al. 2016. StrongNet: an international network to improve diagnostics and access to treatment for strongyloidiasis control. PLoS Negl Trop Dis 10: e0004898.
-
10.
Einsiedel L, Fernandes L, 2008. Strongyloides stercoralis: a cause of morbidity and mortality for indigenous people in central Australia. Intern Med J 38: 697–703.
-
11.
Abdolrasouli A, McMillan A, Ackers JP, 2009. Sexual transmission of intestinal parasites in men who have sex with men. Sex Health 6: 185–194.
-
12.
Qu Z, Kundu UR, Abadeer RA, Wanger A, 2009. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 40: 572–577.
-
13.
Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, Sciberras DG, Hsieh JY, Lasseter KC, 2002. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 1122–1133.
-
14.
Edwards G, 2003. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2 (Suppl 1): S8.
-
15.
González Canga A, Sahagún Prieto AM, Diez-Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ, 2008. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 10: 42–46.
-
16.
Steel JW, 1993. Pharmacokinetics and metabolism of avermectins in livestock. Vet Parasitol 48: 45–57.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 224 | 161 | 19 |
| Full Text Views | 597 | 14 | 0 |
| PDF Downloads | 251 | 14 | 0 |